Cognition Therapeutics Inc (CGTX) Stock Price, Quote & News

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as ge...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 481 2210

Website: www.cogrx.com

Address:

2500 Westchester Ave., Purchase, United States

Rjcamel2355 Feb. 3 at 6:09 PM

$CGTX 2-3 weeks out on the FDA minutes, 4 weeks or less on the EMA meeting. Should hopefully start getting some updates on trials/EAP. Everything is lined up for a great horizon, just a waiting game.

0 · Reply

byeonkh Feb. 3 at 2:04 AM

$CGTX Feels like we’re building a base around $1.15 this week, with a shot at holding $1.20 next week. Hoping for positive EMA/FDA meeting minutes — and maybe some Phase 3 news soon.

0 · Reply

Dmsrz8 Feb. 2 at 4:04 PM

$CGTX only 360k shares traded and green. Shows that last week was certainly some level of manipulation or ATM or a combo. We will be fine

1 · Reply

Rjcamel2355 Feb. 2 at 3:56 PM

$CGTX I don't know about the rest of y'all.......but I bought more during that red day.

1 · Reply

GibsonFlyingV Feb. 2 at 3:49 PM

$CGTX Q: what do red days bring? A: GREEN DAYS!!!!

0 · Reply

MisterSuper Feb. 2 at 3:35 PM

$CGTX After selling for tax losses and waiting a month, I now went back into our little gem

1 · Reply

goldenxb Feb. 2 at 3:09 PM

$CGTX nice!!

0 · Reply

FitzCatalyst Feb. 2 at 3:08 PM

$CGTX 👀

0 · Reply

Aimforsuccess Feb. 2 at 2:41 PM

$CGTX Pretty obvious the financial terrorists are slapping it down. Shorts and market makers in my opinion.

0 · Reply

ERPBlast Feb. 2 at 10:22 AM

$CGTX Again down

1 · Reply

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Jan 6, 2026, 7:30 AM EST - 4 weeks ago

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies

Dec 1, 2025, 7:30 AM EST - 2 months ago

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 20, 2025, 4:01 PM EST - 2 months ago

Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

Nov 13, 2025, 7:36 AM EST - 2 months ago

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease

Nov 6, 2025, 7:30 AM EST - 3 months ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

Sep 3, 2025, 7:30 AM EDT - 5 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

Sep 2, 2025, 4:00 PM EDT - 5 months ago

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

Aug 27, 2025, 8:53 PM EDT - 5 months ago

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

Aug 26, 2025, 4:00 PM EDT - 5 months ago

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 26, 2025, 10:08 AM EDT - 5 months ago

Cognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" Rating

Aug 12, 2025, 4:00 PM EDT - 6 months ago

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

Jul 29, 2025, 7:30 AM EDT - 6 months ago

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

Jul 21, 2025, 7:30 AM EDT - 7 months ago

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

Jul 16, 2025, 7:30 AM EDT - 7 months ago

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

Jul 10, 2025, 7:30 AM EDT - 7 months ago

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

Jul 1, 2025, 7:30 AM EDT - 7 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

Jun 25, 2025, 7:30 AM EDT - 7 months ago

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

Jun 3, 2025, 7:30 AM EDT - 8 months ago

Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

May 28, 2025, 7:30 AM EDT - 8 months ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

May 9, 2025, 7:30 AM EDT - 9 months ago

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

May 7, 2025, 7:30 AM EDT - 9 months ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

Apr 1, 2025, 7:30 AM EDT - 11 months ago

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Mar 25, 2025, 7:30 AM EDT - 11 months ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

Mar 20, 2025, 1:15 PM EDT - 11 months ago

Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:00 AM EDT - 11 months ago

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:05 PM EDT - 11 months ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

Mar 12, 2025, 4:05 PM EDT - 11 months ago

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

Mar 10, 2025, 7:30 AM EDT - 11 months ago

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

Feb 27, 2025, 7:30 AM EST - 1 year ago

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Feb 25, 2025, 7:30 AM EST - 1 year ago

Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

Jan 30, 2025, 7:30 AM EST - 1 year ago

Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Jan 8, 2025, 4:14 PM EST - 1 year ago

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Dec 18, 2024, 11:06 AM EST - 1 year ago

Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?

Dec 18, 2024, 7:22 AM EST - 1 year ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Nov 26, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Nov 25, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Nov 12, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Oct 31, 2024, 4:15 PM EDT - 1 year ago

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Oct 29, 2024, 12:55 PM EDT - 1 year ago

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

Aug 22, 2024, 7:31 AM EDT - 1 year ago

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

Aug 11, 2024, 12:55 AM EDT - 1 year ago

Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

Rjcamel2355 Feb. 3 at 6:09 PM

$CGTX 2-3 weeks out on the FDA minutes, 4 weeks or less on the EMA meeting. Should hopefully start getting some updates on trials/EAP. Everything is lined up for a great horizon, just a waiting game.

0 · Reply

byeonkh Feb. 3 at 2:04 AM

$CGTX Feels like we’re building a base around $1.15 this week, with a shot at holding $1.20 next week. Hoping for positive EMA/FDA meeting minutes — and maybe some Phase 3 news soon.

0 · Reply

Dmsrz8 Feb. 2 at 4:04 PM

$CGTX only 360k shares traded and green. Shows that last week was certainly some level of manipulation or ATM or a combo. We will be fine

1 · Reply

Rjcamel2355 Feb. 2 at 3:56 PM

$CGTX I don't know about the rest of y'all.......but I bought more during that red day.

1 · Reply

GibsonFlyingV Feb. 2 at 3:49 PM

$CGTX Q: what do red days bring? A: GREEN DAYS!!!!

0 · Reply

MisterSuper Feb. 2 at 3:35 PM

$CGTX After selling for tax losses and waiting a month, I now went back into our little gem

1 · Reply

goldenxb Feb. 2 at 3:09 PM

$CGTX nice!!

0 · Reply

FitzCatalyst Feb. 2 at 3:08 PM

$CGTX 👀

0 · Reply

Aimforsuccess Feb. 2 at 2:41 PM

$CGTX Pretty obvious the financial terrorists are slapping it down. Shorts and market makers in my opinion.

0 · Reply

ERPBlast Feb. 2 at 10:22 AM

$CGTX Again down

1 · Reply

BarryLong28 Feb. 1 at 7:54 PM

$CGTX Might be another rough week in the market, but Barry Long is Long and Strong!

2 · Reply

nostic Jan. 31 at 1:07 AM

$CGTX Possibly some, but most of the small caps I track were down 5-12% today. When rate expectations change, my guess is algos and funds that work off discounted cash flow modeling re-value stocks. Rate expectations changed with the new Fed chair appointee today (being less dovish than the expected person, even though I think ultimately that won’t be the case). Contributed to silver crashing too. Anyway, that’s why small caps got wrecked today.

2 · Reply

stevensco Jan. 30 at 10:54 PM

$CGTX dropping like a stone

2 · Reply

byeonkh Jan. 30 at 10:41 PM

$CGTX This drop looks largely ATM-driven to me. Out of around 2M shares in volume, I’d guess half or more came from ATM, just my opinion. Could also be shorts or some institutional rebalancing, but ATM feels like the main cause. Definitely not easy, and February may be tough as well.

0 · Reply

Aimforsuccess Jan. 30 at 10:08 PM

$CGTX Looks like Lisa needs to get off her besides and get something done. The FDA release was pathetic at best and it’s easy to see why many interpreted it negatively. Is she working on a capital raise behind the scenes? That could leak very easily and be a sign of dilution. Yes, I think the stock is heavily manipulated, but this downward move, smells of poor management.

1 · Reply

shadow2356 Jan. 30 at 9:45 PM

$CGTX Ugghh. Getting close to getting delisted again I am trying to remain hopeful.

1 · Reply

Rjcamel2355 Jan. 30 at 9:03 PM

$CGTX what a disgusting blood bath this week has been. I remain positive, long and strong, optimistic and hopeful for the company and the drug. Nothing has changed for me, and I will continue to add.

1 · Reply

Itinerant Jan. 30 at 8:43 PM

$CGTX Why is this being manipulated down? The Street knows something. What is it? Theories? Nothing happens without a reason.

2 · Reply

everything5 Jan. 30 at 8:38 PM

$CGTX A lot of competition in this arena.

0 · Reply

agarfield Jan. 30 at 7:42 PM

$CGTX This is an investment, in more ways than one: https://www.bannerhealth.com/newsroom/press-releases/lewy-body-research

1 · Reply

Silvercaine Jan. 30 at 7:07 PM

$CGTX yup, half a mil shorted fee min ago. Their piling in....

1 · Reply

goldenxb Jan. 30 at 6:17 PM

$CGTX what the actual f? very disappointing

0 · Reply

Market Cap	96.22M
Revenue (ttm)	0.00
Net Income (ttm)	-33.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	372,051
Avg Vol	976,264
Day's Range	N/A - N/A
Shares Out	88.27M
Stochastic %K	16%
Beta	1.26
Analysts	Strong Sell
Price Target	$3.50